Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
1997

Study of Irinotecan and Etoposide for Lung Cancer

Sample size: 27 publication Evidence: low

Author Information

Author(s): M Andol, K Eguchi, T Shinkai, T Tamura, Y Ohe, N Yamamoto, T Kurata, T Kasai, H Ohmatsu, K Kubota, I Sekine, N Hojo, T Matsumoto, T Kodama, R Kakinuma, Y Nishiwaki, N Saijo

Primary Institution: National Cancer Center Hospital

Hypothesis

Can sequential administration of irinotecan and etoposide improve treatment outcomes for metastatic non-small-cell lung cancer?

Conclusion

The sequential administration of irinotecan and etoposide resulted in severe toxicities, making the treatment regimens inappropriate for further assessment.

Supporting Evidence

  • Two out of five patients in arm A achieved partial response.
  • One out of four patients in arm B achieved partial response.
  • Major dose-limiting toxicities included granulocytopenia and diarrhea.

Takeaway

Doctors tested two cancer drugs together to see if they could help patients with lung cancer, but the side effects were too strong to continue.

Methodology

Patients were randomly assigned to two treatment arms receiving irinotecan and etoposide in different sequences, with G-CSF support.

Limitations

The sample size was too small to detect differences in toxicities between the two arms.

Participant Demographics

{"total_patients":28,"assessable_patients":27,"age_mean":60,"sex_ratio":"16:12 male to female"}

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication